BR112016028958A2 - método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento - Google Patents

método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento

Info

Publication number
BR112016028958A2
BR112016028958A2 BR112016028958A BR112016028958A BR112016028958A2 BR 112016028958 A2 BR112016028958 A2 BR 112016028958A2 BR 112016028958 A BR112016028958 A BR 112016028958A BR 112016028958 A BR112016028958 A BR 112016028958A BR 112016028958 A2 BR112016028958 A2 BR 112016028958A2
Authority
BR
Brazil
Prior art keywords
treatment
level
micrornate
individual
composition
Prior art date
Application number
BR112016028958A
Other languages
English (en)
Inventor
Johannes Grillari
Regina Grillari
Matthias Hackl
Elisabeth Schraml
Sylvia Weilner
Original Assignee
Univ Wien Bodenkultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Bodenkultur filed Critical Univ Wien Bodenkultur
Publication of BR112016028958A2 publication Critical patent/BR112016028958A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

?método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento?. a presente invenção se refere à terapia, à profilaxia e ao diagnóstico de disfunções associadas a uma densidade mineral óssea anormal, especificamente, à osteoporose; em que é detectado o nível dos micrornas selecionados nas amostras de pacientes e em que um aumento ou diminuição de dito nível comparado ao nível de indivíduos saudáveis é indicativo da disfunção.
BR112016028958A 2014-06-13 2015-06-11 método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento BR112016028958A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172354 2014-06-13
EP14198560 2014-12-17
PCT/EP2015/063091 WO2015189345A2 (en) 2014-06-13 2015-06-11 Compositions and methods for the diagnosis and treatment of bone fractures and disorders

Publications (1)

Publication Number Publication Date
BR112016028958A2 true BR112016028958A2 (pt) 2017-10-31

Family

ID=53373478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028958A BR112016028958A2 (pt) 2014-06-13 2015-06-11 método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento

Country Status (9)

Country Link
US (1) US10125398B2 (pt)
EP (1) EP3155120B1 (pt)
JP (2) JP6841661B2 (pt)
CN (1) CN106687602B (pt)
BR (1) BR112016028958A2 (pt)
CA (1) CA2948224A1 (pt)
DK (1) DK3155120T5 (pt)
ES (1) ES2704748T3 (pt)
WO (1) WO2015189345A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098052A1 (en) * 2015-12-10 2017-06-15 Universität Für Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
CN106834442A (zh) * 2016-12-30 2017-06-13 王春庆 miR‑144‑3p在制备骨质疏松诊断标志物中的应用
CN106591487A (zh) * 2017-02-22 2017-04-26 西北工业大学 老年骨质疏松性骨折的血清microRNA诊断标志物及其诊断试剂盒
JP7118046B2 (ja) * 2017-03-02 2022-08-15 第一三共株式会社 オピオイド薬の治療有効性を予測するためのｍｉｃｒｏＲＮＡバイオマーカー
CN107184605A (zh) * 2017-06-06 2017-09-22 太原市博菲科特生物科技有限公司 一种治疗脊髓损伤的药物及其应用
CN107312778B (zh) * 2017-07-21 2018-10-12 广州达雅高桐树医学检验实验室有限公司 一种癌症诊断试剂盒以及治疗用药物组合物
CN107475380A (zh) * 2017-08-10 2017-12-15 深圳市第二人民医院 与骨折愈合相关的miRNA标志物及其检测引物和应用
CN107693535A (zh) * 2017-09-05 2018-02-16 上海市光华中西医结合医院 一种microRNA的应用
CN107723365B (zh) * 2017-09-11 2019-10-01 朱伟 一种与肺鳞癌辅助诊断相关的血浆miRNA标志物及其应用
JP2019050772A (ja) * 2017-09-15 2019-04-04 国立大学法人 熊本大学 ワクチン接種後副反応を予測する検査方法
JP6948059B2 (ja) * 2017-09-28 2021-10-13 学校法人 川崎学園 ｍｉＲ−１４０−３ｐによる骨芽細胞からのオステオカルシン産生促進
CN107513571B (zh) * 2017-09-30 2020-07-07 首都医科大学附属北京口腔医院 miRNA的应用
CN109722474A (zh) * 2017-10-31 2019-05-07 中国科学院深圳先进技术研究院 与骨代谢疾病相关的miRNA标志物miR-19b及其应用
CN109722473A (zh) * 2017-10-31 2019-05-07 中国科学院深圳先进技术研究院 与骨代谢疾病相关的miRNA标志物miR-19b的应用
CN113116918B (zh) * 2017-12-29 2022-06-14 中国科学院上海药物研究所 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用
CN108559773A (zh) * 2018-04-18 2018-09-21 江苏省人民医院（南京医科大学第附属医院） miR-218在制备治疗骨质疏松症药物中的应用
CN108424962B (zh) * 2018-05-25 2021-08-03 中国人民解放军陆军军医大学 系膜增生性肾小球肾炎的miRNA检测标志物及其诊断试剂盒
US10987428B2 (en) * 2018-06-01 2021-04-27 City Of Hope Phosphorothioate-conjugated miRNAs and methods of using the same
JP6938584B2 (ja) * 2018-08-30 2021-09-22 台湾基督長老教会馬偕医療財団法人馬偕紀念医院 細胞外小胞による疾患の診断方法
CN110117647B (zh) * 2018-11-30 2022-10-18 首都医科大学附属北京潞河医院 成人隐匿性自身免疫性糖尿病相关的microRNA及相关应用
CN109652529B (zh) * 2018-12-27 2021-09-24 固安博健生物技术有限公司 骨质疏松特异性miRNA、组合物及其诊疗用途
CN111850107A (zh) * 2019-04-24 2020-10-30 华东医院 microRNA-200簇微小RNA在促进骨髓间充质干细胞向成骨细胞分化的应用
US20220409652A1 (en) * 2019-11-29 2022-12-29 Novadip Biosciences miRNA-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND THE TREATMENT OF TISSUE DISORDERS
CN110946873B (zh) * 2019-12-16 2021-08-24 山东大学齐鲁医院 microRNA-29a-3p作为胶质瘤血管拟态防治靶点的应用
CN112080500B (zh) * 2020-08-21 2022-02-18 中南大学湘雅二医院 制备诊断和治疗1型糖尿病药物的分子靶标及其应用
CN112725268B (zh) * 2021-01-28 2021-10-01 广东新征程生命科学有限公司 一种促进脂肪干细胞成骨分化的组合物及其应用
CN114107476A (zh) * 2021-04-12 2022-03-01 上海市同仁医院 miR-29在骨质疏松中的应用
CN114292847B (zh) * 2021-12-31 2023-10-03 川北医学院附属医院 一种长链非编码rna及其在制备治疗骨质疏松药物中的应用
CN114480621A (zh) * 2022-01-26 2022-05-13 上海生物芯片有限公司 用于细胞上清外泌体miRNA检测的内参基因
TWI828096B (zh) * 2022-03-25 2024-01-01 英屬開曼群島商百蒂醫股份有限公司 X光影像分析方法
WO2024100072A1 (en) * 2022-11-08 2024-05-16 Ospedale Galeazzi S.P.A. Mirna-based biomarker for muscle wasting in osteoporotic patients
CN117373681B (zh) * 2023-10-30 2024-04-26 中国航天科工集团七三一医院 一种基于血糖调节系统作用的骨折愈合仿真方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CA2597605A1 (en) * 2005-02-16 2006-08-24 The Regents Of The University Of California Pharmaceutical compositions for treating or preventing bone conditions
GB0517466D0 (en) * 2005-08-26 2005-10-05 Immunodiagnostic Systems Plc Diagnostic assay and therapeutic treatment
US8440637B2 (en) * 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
AU2009283906A1 (en) * 2008-08-19 2010-02-25 Maine Institute For Human Genetics And Health Micro RNA and Neurofibromatosis Type 1 in diagnosis and therapy
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
BR112012029656A2 (pt) * 2010-05-21 2016-12-13 Uni Fur Bodenkultur Wien composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares
WO2013155085A1 (en) * 2012-04-09 2013-10-17 Creighton University Methods and biomarkers for osteoporosis

Also Published As

Publication number Publication date
ES2704748T3 (es) 2019-03-19
JP2020162610A (ja) 2020-10-08
CN106687602A (zh) 2017-05-17
CN106687602B (zh) 2021-12-28
DK3155120T5 (en) 2019-01-28
JP6841661B2 (ja) 2021-03-10
WO2015189345A2 (en) 2015-12-17
CA2948224A1 (en) 2015-12-17
JP2017518753A (ja) 2017-07-13
US20170130268A1 (en) 2017-05-11
US10125398B2 (en) 2018-11-13
EP3155120A2 (en) 2017-04-19
EP3155120B1 (en) 2018-10-17
WO2015189345A3 (en) 2016-02-04
DK3155120T3 (en) 2019-01-21

Similar Documents

Publication Publication Date Title
BR112016028958A2 (pt) método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112014029655A2 (pt) dispositivo para preparar tecido, e método para preparar tecido
WO2014179765A3 (en) Novel human mirnas for use in diagnosis, prognosis and therapy of human conditions and diseases
IL282923A (en) Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
BR112015018213A2 (pt) método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
EA201790444A1 (ru) Hsp90-направленная визуализация и терапия воспаления и инфекции
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112015000685A2 (pt) método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
BR112015005583A2 (pt) método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica
WO2015115923A3 (en) A profile of microrna in the blood as a test for the detection of lung cancer
BR112014002404A2 (pt) oligonucleotídeo, iniciador, par de iniciadores, sonda, kit, métodos para determinar se o gene prame é expressado em uma amostra biológica, de diagnose de paciente, para determinar a presença ou ausência de tecido de tumor positive, e de tratamento de um paciente, e, composição
TW201612520A (en) Tumor examination composition and test paper for tumor examination
EA201600668A3 (ru) Способ мониторинга эффективности противоопухолевой терапии немелкоклеточного рака легкого
BR112013032238A2 (pt) método para a determinação de uma variação do volume plasmático e dispositivos para implementar o método
UA106254U (uk) Спосіб прогнозування зрощення перелому
FI20150314A (fi) Menetelmä rintojen tutkimiseksi ja kasvaimien todentamiseksi kudoksessa eri taajuuksilla ilmenevien fysiologisten ilmiöiden ja muutosten perusteella, käytettäväksi yhdessä tai erikseen mammografiatutkimuksen kanssa nostamaan tutkimusten sensitiivisyyttä ja spesifisyyttä
UA83488U (uk) Спосіб оцінки антиоксидантної активності комплексної терапії, що включає мексикор, у хворих стабільною стенокардією на фоні ожиріння
UA106732U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.